PURPOSE: To evaluate the prevalence and severity of clinical adverse events (AEs) and treatment-related risk factors in childhood cancer survivors treated with cranial radiation therapy (CRT), with the aim of assessing dose-effect relationships. METHODS AND MATERIALS: The retrospective study cohort consisted of 1362 Dutch childhood cancer survivors, of whom 285 were treated with CRT delivered as brain irradiation (BI), as part of craniospinal irradiation (CSI), and as total body irradiation (TBI). Individual CRT doses were converted into the equivalent dose in 2-Gy fractions (EQD(2)). Survivors had received their diagnoses between 1966 and 1996 and survived at least 5 years after diagnosis. A complete inventory of Common Terminology Criteria for Adverse Events grade 3.0 AEs was available from our hospital-based late-effect follow-up program. We used multivariable logistic and Cox regression analyses to examine the EQD(2) in relation to the prevalence and severity of AEs, correcting for sex, age at diagnosis, follow-up time, and the treatment-related risk factors surgery and chemotherapy. RESULTS: There was a high prevalence of AEs in the CRT group; over 80% of survivors had more than 1 AE, and almost half had at least 5 AEs, both representing significant increases in number of AEs compared with survivors not treated with CRT. Additionally, the proportion of severe, life-threatening, or disabling AEs was significantly higher in the CRT group. The most frequent AEs were alopecia and cognitive, endocrine, metabolic, and neurologic events. Using the EQD(2), we found significant dose-effect relationships for these and other AEs. CONCLUSION: Our results confirm that CRT increases the prevalence and severity of AEs in childhood cancer survivors. Furthermore, analyzing dose-effect relationships with the cumulative EQD(2) instead of total physical dose connects the knowledge from radiation therapy and radiobiology with the clinical experience.
PURPOSE: To evaluate the prevalence and severity of clinical adverse events (AEs) and treatment-related risk factors in childhood cancer survivors treated with cranial radiation therapy (CRT), with the aim of assessing dose-effect relationships. METHODS AND MATERIALS: The retrospective study cohort consisted of 1362 Dutch childhood cancer survivors, of whom 285 were treated with CRT delivered as brain irradiation (BI), as part of craniospinal irradiation (CSI), and as total body irradiation (TBI). Individual CRT doses were converted into the equivalent dose in 2-Gy fractions (EQD(2)). Survivors had received their diagnoses between 1966 and 1996 and survived at least 5 years after diagnosis. A complete inventory of Common Terminology Criteria for Adverse Events grade 3.0 AEs was available from our hospital-based late-effect follow-up program. We used multivariable logistic and Cox regression analyses to examine the EQD(2) in relation to the prevalence and severity of AEs, correcting for sex, age at diagnosis, follow-up time, and the treatment-related risk factors surgery and chemotherapy. RESULTS: There was a high prevalence of AEs in the CRT group; over 80% of survivors had more than 1 AE, and almost half had at least 5 AEs, both representing significant increases in number of AEs compared with survivors not treated with CRT. Additionally, the proportion of severe, life-threatening, or disabling AEs was significantly higher in the CRT group. The most frequent AEs were alopecia and cognitive, endocrine, metabolic, and neurologic events. Using the EQD(2), we found significant dose-effect relationships for these and other AEs. CONCLUSION: Our results confirm that CRT increases the prevalence and severity of AEs in childhood cancer survivors. Furthermore, analyzing dose-effect relationships with the cumulative EQD(2) instead of total physical dose connects the knowledge from radiation therapy and radiobiology with the clinical experience.
Authors: Ziyuan Wang; Marco Virgolin; Peter A N Bosman; Koen F Crama; Brian V Balgobind; Arjan Bel; Tanja Alderliesten Journal: J Med Imaging (Bellingham) Date: 2020-02-03
Authors: Irma W E M van Dijk; Rob M van Os; Jeroen B van de Kamer; Nicolaas A P Franken; Helena J H van der Pal; Caro C E Koning; Huib N Caron; Cécile M Ronckers; Leontien C M Kremer Journal: J Cancer Surviv Date: 2014-06-14 Impact factor: 4.442
Authors: E Sieswerda; R L Mulder; I W E M van Dijk; E C van Dalen; S L Knijnenburg; H J H van der Pal; M S Mud; R C Heinen; H N Caron; L C M Kremer Journal: J Cancer Surviv Date: 2013-04-30 Impact factor: 4.442
Authors: Gregory S Phillips; Morgan E Freret; Danielle Novetsky Friedman; Sabrina Trelles; Oluwaseun Kukoyi; Azael Freites-Martinez; Robin H Unger; Joseph J Disa; Leonard H Wexler; Christopher L Tinkle; James G Mechalakos; Stephen W Dusza; Kathryn Beal; Suzanne L Wolden; Mario E Lacouture Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers Journal: Nat Rev Endocrinol Date: 2016-04-01 Impact factor: 43.330
Authors: Talitha de Siqueira Mellara; Regina Guenka Palma-Dibb; Harley Francisco de Oliveira; Francisco Wanderley Garcia Paula-Silva; Paulo Nelson-Filho; Raquel Assed Bezerra da Silva; Léa Assed Bezerra da Silva; Alexandra Mussolino de Queiroz Journal: Radiat Oncol Date: 2014-01-22 Impact factor: 3.481
Authors: Kirsten K Ness; Melissa M Hudson; Kendra E Jones; Wendy Leisenring; Yutaka Yasui; Yan Chen; Marilyn Stovall; Todd M Gibson; Daniel M Green; Joseph P Neglia; Tara O Henderson; Jacqueline Casillas; Jennifer S Ford; Karen E Effinger; Kevin R Krull; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Paul C Nathan Journal: Ann Intern Med Date: 2016-11-08 Impact factor: 25.391
Authors: Anna Sällfors Holmqvist; Christian Moëll; Lars Hjorth; Anna Lindgren; Stanislaw Garwicz; Thomas Wiebe; Ingrid Øra Journal: BMC Cancer Date: 2014-06-10 Impact factor: 4.430